Candid Therapeutics signs $925m T cell engager deal with WuXi Biologics
US-based Candid Therapeutics has signed another T-cell engager (TCE) partnership, this time with Chinese biotech WuXi Biologics for the global …
US-based Candid Therapeutics has signed another T-cell engager (TCE) partnership, this time with Chinese biotech WuXi Biologics for the global …
WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately …
The US Food and Drug Administration (FDA) has accepted for filing and priority review of the new drug application (NDA) …
The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective peroxisome proliferator-activated receptor …
COVID-19, caused by the SARS-CoV-2 virus, has profoundly reshaped global healthcare since its emergence in December 2019. By 2024, the …
Denmark-based biotech Orbis Medicines has raised €90m ($94m) in a Series A funding round to advance the development of its …
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD Pharma’s oral lead development programme, …
The European Commission (EC) has extended the approval of Ultragenyx Pharmaceutical’s Evkeeza (evinacumab) to include children aged six months to …
Amgen has said the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) conditional approval of Imdylltra (tarlatamab) for extensive-stage small …
With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market …
The Abu Dhabi Stem Cells Center (ADSCC) in the UAE has developed clinical-grade induced pluripotent stem cells (iPSCs) that meet …
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to …
BNT-325 is under clinical development by BioNTech and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II …
Coronavirus Disease 2019 (COVID-19) vaccine is under clinical development by China National Biotec Group and currently in Phase III for …
Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders. …